Rein Therapeutics Inc. RNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.47% | -15.58% | -20.89% | 62.24% | -51.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.57% | -6.76% | -31.71% | -9.54% | -23.98% |
| Operating Income | 11.57% | 6.76% | 31.71% | 9.54% | 23.98% |
| Income Before Tax | 6.55% | -6.13% | 23.15% | 4.55% | 23.71% |
| Income Tax Expenses | -- | -- | 53.89% | -- | -- |
| Earnings from Continuing Operations | 6.55% | -6.13% | 22.00% | 4.55% | 23.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.55% | -6.13% | 22.00% | 4.55% | 23.71% |
| EBIT | 11.57% | 6.76% | 31.71% | 9.54% | 23.98% |
| EBITDA | 11.57% | 6.50% | 31.71% | 9.54% | 23.96% |
| EPS Basic | 73.65% | 17.05% | 42.18% | 21.56% | 37.21% |
| Normalized Basic EPS | 73.62% | 17.08% | 46.61% | 21.58% | 37.19% |
| EPS Diluted | 73.65% | 17.05% | 42.18% | 21.56% | 37.21% |
| Normalized Diluted EPS | 73.62% | 17.08% | 46.61% | 21.58% | 37.19% |
| Average Basic Shares Outstanding | 254.59% | 27.94% | 34.91% | 21.69% | 21.48% |
| Average Diluted Shares Outstanding | 254.59% | 27.94% | 34.91% | 21.69% | 21.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |